CN102575295B - 可用于检测braf突变的方法、引物、探针和试剂盒 - Google Patents
可用于检测braf突变的方法、引物、探针和试剂盒 Download PDFInfo
- Publication number
- CN102575295B CN102575295B CN201080045765.7A CN201080045765A CN102575295B CN 102575295 B CN102575295 B CN 102575295B CN 201080045765 A CN201080045765 A CN 201080045765A CN 102575295 B CN102575295 B CN 102575295B
- Authority
- CN
- China
- Prior art keywords
- sequence
- braf
- sample
- primer
- seqidno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000008859 change Effects 0.000 title claims abstract description 72
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 title claims abstract description 69
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 title claims abstract description 68
- 238000012360 testing method Methods 0.000 title claims description 16
- 238000001514 detection method Methods 0.000 title claims description 8
- 239000000523 sample Substances 0.000 title abstract description 56
- 238000000034 method Methods 0.000 title abstract description 36
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 238000000137 annealing Methods 0.000 claims description 5
- 208000021039 metastatic melanoma Diseases 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 2
- 102200055464 rs113488022 Human genes 0.000 abstract description 20
- 102220197820 rs121913227 Human genes 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000003321 amplification Effects 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 201000010989 colorectal carcinoma Diseases 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000032818 Microsatellite Instability Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108091092878 Microsatellite Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 229910015837 MSH2 Inorganic materials 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000003192 autonomic ganglia Anatomy 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
- 101150061338 mmr gene Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23305409P | 2009-08-11 | 2009-08-11 | |
| US61/233,054 | 2009-08-11 | ||
| US23707809P | 2009-08-26 | 2009-08-26 | |
| US61/237,078 | 2009-08-26 | ||
| US30179010P | 2010-02-05 | 2010-02-05 | |
| US61/301,790 | 2010-02-05 | ||
| PCT/US2010/044997 WO2011019704A2 (en) | 2009-08-11 | 2010-08-10 | Methods, primers, probes and kits useful for the detection of braf mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102575295A CN102575295A (zh) | 2012-07-11 |
| CN102575295B true CN102575295B (zh) | 2016-02-17 |
Family
ID=43586772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080045765.7A Expired - Fee Related CN102575295B (zh) | 2009-08-11 | 2010-08-10 | 可用于检测braf突变的方法、引物、探针和试剂盒 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140248614A1 (enExample) |
| EP (1) | EP2464751B1 (enExample) |
| JP (1) | JP2013501523A (enExample) |
| KR (1) | KR20120099630A (enExample) |
| CN (1) | CN102575295B (enExample) |
| AR (1) | AR077844A1 (enExample) |
| AU (1) | AU2010282632A1 (enExample) |
| CA (1) | CA2770716A1 (enExample) |
| IL (1) | IL218021A0 (enExample) |
| NZ (1) | NZ598166A (enExample) |
| TW (1) | TW201111517A (enExample) |
| WO (1) | WO2011019704A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6153758B2 (ja) * | 2012-04-20 | 2017-06-28 | アークレイ株式会社 | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット |
| US10077474B2 (en) | 2012-05-29 | 2018-09-18 | Abbott Molecular, Inc. | Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits |
| CN102816851A (zh) * | 2012-08-29 | 2012-12-12 | 苏州旷远生物分子技术有限公司 | 用于检测braf基因v600e突变的引物、探针、试剂盒及方法 |
| CN102876784B (zh) * | 2012-09-13 | 2014-11-19 | 周宏灏 | 焦磷酸测序法检测B-raf基因多态性的试剂盒及方法 |
| EP2711432A1 (en) * | 2012-09-21 | 2014-03-26 | Genomica S.A.U. | Method for detection of BRAF and PI3K mutations |
| EP3473250B1 (en) | 2012-12-27 | 2022-08-17 | Quest Diagnostics Investments Incorporated | Ddr2 mutations as targetable features of melanoma or basal cell carcinoma |
| CN103103269B (zh) * | 2013-01-18 | 2015-07-15 | 陕西佰美基因股份有限公司 | 一种基于探针熔解技术准确检测braf基因突变的方法 |
| JP2016512041A (ja) * | 2013-03-15 | 2016-04-25 | アボツト・モレキユラー・インコーポレイテツド | 多重対立遺伝子の検出 |
| KR101378920B1 (ko) * | 2013-04-18 | 2014-03-27 | 주식회사 현일바이오 | Ｂｒａｆ 돌연변이의 선택적 검출 방법 및 이를 이용한 키트 |
| US20160108479A1 (en) * | 2013-08-14 | 2016-04-21 | Qiagen Mansfield, Inc. | Compositions and methods for multiplex analysis of nras and braf nucleic acids |
| CN104017887A (zh) * | 2014-06-18 | 2014-09-03 | 广州好芝生物科技有限公司 | 人类braf基因突变检测引物对和探针及其试剂盒 |
| CA2954689A1 (en) * | 2014-07-11 | 2016-01-14 | Expression Pathology, Inc. | Srm/mrm assay for the serine/threonine-protein kinase b-raf (braf) |
| CN105400900A (zh) * | 2015-12-29 | 2016-03-16 | 杭州迪安生物技术有限公司 | 焦磷酸测序技术检测braf基因v600e微量突变试剂盒及其应用 |
| CN105861691A (zh) * | 2016-05-06 | 2016-08-17 | 北京晋祺生物科技有限公司 | 一种braf基因突变检测的引物组合物、试剂盒及方法 |
| US12364776B2 (en) | 2017-06-29 | 2025-07-22 | Korea Advanced Institute Of Science And Technology | Ganglioglioma-induced animal model and a method for diagnosing and treating ganglioglioma and related diseases |
| KR20190038464A (ko) * | 2017-09-29 | 2019-04-08 | (재)록원바이오융합연구재단 | Ras/braf 돌연변이 검출용 조성물 및 이를 포함하는 키트 |
| CN109161594A (zh) * | 2018-08-17 | 2019-01-08 | 中山大学达安基因股份有限公司 | 一种检测braf基因突变的方法及其试剂盒 |
| WO2022119423A1 (ko) * | 2020-12-04 | 2022-06-09 | 주식회사 제노픽스 | 폐암 유전자 돌연변이 초고감도 선택적 증폭 방법 및 이를 위한 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101487051A (zh) * | 2009-02-24 | 2009-07-22 | 广州益善生物技术有限公司 | Braf基因突变的检测探针、液相芯片及其检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004337120A (ja) * | 2003-05-19 | 2004-12-02 | Chang Gung Univ | 膀胱癌再発検査方法 |
| US7745125B2 (en) * | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
-
2010
- 2010-08-10 NZ NZ598166A patent/NZ598166A/en not_active IP Right Cessation
- 2010-08-10 CN CN201080045765.7A patent/CN102575295B/zh not_active Expired - Fee Related
- 2010-08-10 JP JP2012524782A patent/JP2013501523A/ja active Pending
- 2010-08-10 KR KR1020127004699A patent/KR20120099630A/ko not_active Ceased
- 2010-08-10 CA CA2770716A patent/CA2770716A1/en not_active Abandoned
- 2010-08-10 WO PCT/US2010/044997 patent/WO2011019704A2/en not_active Ceased
- 2010-08-10 EP EP10808619.0A patent/EP2464751B1/en not_active Not-in-force
- 2010-08-10 AU AU2010282632A patent/AU2010282632A1/en not_active Abandoned
- 2010-08-11 TW TW099126740A patent/TW201111517A/zh unknown
- 2010-08-11 AR ARP100102935A patent/AR077844A1/es unknown
-
2012
- 2012-02-09 IL IL218021A patent/IL218021A0/en unknown
-
2014
- 2014-02-27 US US14/192,414 patent/US20140248614A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101487051A (zh) * | 2009-02-24 | 2009-07-22 | 广州益善生物技术有限公司 | Braf基因突变的检测探针、液相芯片及其检测方法 |
Non-Patent Citations (2)
| Title |
|---|
| Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma;YANCOVITZ等;《Journal of Molecular Diagnostics》;20070430;第9卷(第2期);摘要、材料与方法 * |
| Real-time allele-specific amplification for sensitive detection of the BRAFmutation V600E;JARRY.A.等;《Materials and Method》;20041031;第18卷(第5期);第349-352页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011019704A3 (en) | 2011-07-07 |
| CN102575295A (zh) | 2012-07-11 |
| EP2464751A4 (en) | 2013-07-03 |
| KR20120099630A (ko) | 2012-09-11 |
| AU2010282632A1 (en) | 2012-03-08 |
| IL218021A0 (en) | 2012-04-30 |
| AR077844A1 (es) | 2011-09-28 |
| NZ598166A (en) | 2014-03-28 |
| TW201111517A (en) | 2011-04-01 |
| EP2464751A2 (en) | 2012-06-20 |
| EP2464751B1 (en) | 2017-05-24 |
| JP2013501523A (ja) | 2013-01-17 |
| WO2011019704A2 (en) | 2011-02-17 |
| US20140248614A1 (en) | 2014-09-04 |
| CA2770716A1 (en) | 2011-02-17 |
| HK1172931A1 (zh) | 2013-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102575295B (zh) | 可用于检测braf突变的方法、引物、探针和试剂盒 | |
| US7700286B2 (en) | Method for the detection of cancer | |
| CN109890394A (zh) | 作为子宫内膜异位症的生物标志物的微小rna | |
| Ballester et al. | Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results | |
| CN107849606A (zh) | 提高下一代测序灵敏度的方法 | |
| JP6606554B2 (ja) | Ｙ染色体のメチル化部位を前立腺ガンの診断用マーカとする使用 | |
| EP2877596A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
| US8728763B2 (en) | Methods, primers, probes and kits useful for the detection of BRAF mutations | |
| CN110117652A (zh) | 肝癌早期诊断方法 | |
| CN109055555A (zh) | 一种肺癌早期转移诊断标志物及其试剂盒和应用 | |
| EP3368684B1 (en) | Biomarker for breast cancer | |
| Ida et al. | Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: histological features for accurate diagnosis and toward future novel therapies | |
| US9617603B2 (en) | Method for the urinary detection of bladder cancer | |
| CN106498062A (zh) | 一种诊断前列腺癌的产品及其应用 | |
| Corless | Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testing | |
| US20210189504A1 (en) | Method and kit for measurement of rna | |
| Low et al. | Molecular exploration of paediatric intracranial germinomas from multi-ethnic Singapore | |
| US20190276896A1 (en) | Methods and materials for detecting gene amplification | |
| CN111607646A (zh) | 一种用于检测braf基因突变的核苷酸序列组及其应用 | |
| US20230358749A1 (en) | Early cancer diagnosis method and diagnostic kit using interferon gamma gene concentration measurement in exosomes | |
| Mahmoud et al. | Clinical Impact of IDH1 Mutations and MGMT Methylation in Adult Glioblastoma Multiforme | |
| CN111607593A (zh) | 一种用于检测egfr基因突变的核苷酸序列组及其应用 | |
| HK1172931B (en) | Methods, primers, probes and kits useful for the detection of braf mutations | |
| CN115851959A (zh) | 一种用于食管鳞状细胞癌及癌前病变的诊断或辅助诊断的试剂及检测试剂盒 | |
| CN108753961A (zh) | Braf v600e基因突变检测引物、方法及试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1172931 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1172931 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160217 Termination date: 20200810 |